Torsten is since more than 20 years in pharmaceutical R&D. He is inventor of the anti-emetic medicine Netupitant, FDA approved as Akynzeo© in 2014, and since 2015 recommended by the National Comprehensive Cancer Network for preferred use. At Roche, he created a new R&D department and delivered later 52 new lead series into lead optimization, 32 small molecules into regulatory Tox studies, and more than 25 NCEs into clinical studies over 8 years. Over past 6 years, Torsten is in leading roles and as Scientific Advisory Board member in the European biotechnology industry, successfully prioritized and advanced strong R&D portfolios, and implemented novel approaches to encourage and enable innovation. Currently he is SVP Drug Discovery at Taros in Germany. Torsten authored more than 95 publications, patent applications and published conference reports.